Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

Yu Ri Kim, Jinseok Kim, Soo Jeong Kim, Hyun Ae Jung, Seok Jin Kim, Won Seog Kim, Hye Won Lee, Hyeon Seok Eom, Seong Hyun Jeong, Joon Seong Park, June Won Cheong, Yoo Hong Min

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Abstract. Background: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy. Methods. A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included. Results: Thirty-six patients (30.5%) had a low absolute lymphocyte count (ALC, < 1.0 × 10 9 /L) at diagnosis. Patients with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/ high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was 25.0% in the low ALC group and 4.8% in the high ALC group (P = 0.003). In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P = 0.002, P = 0.001, respectively). Conclusion: This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.

Original languageEnglish
Article number34
JournalJournal of Hematology and Oncology
Volume4
DOIs
Publication statusPublished - 2011 Aug 17

Fingerprint

Peripheral T-Cell Lymphoma
Lymphopenia
Anthracyclines
Drug Therapy
Disease-Free Survival
Survival
T-Cell Lymphoma
Lymphocyte Count
Multivariate Analysis
Survival Rate
Mortality

All Science Journal Classification (ASJC) codes

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Kim, Yu Ri ; Kim, Jinseok ; Kim, Soo Jeong ; Jung, Hyun Ae ; Kim, Seok Jin ; Kim, Won Seog ; Lee, Hye Won ; Eom, Hyeon Seok ; Jeong, Seong Hyun ; Park, Joon Seong ; Cheong, June Won ; Min, Yoo Hong. / Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. In: Journal of Hematology and Oncology. 2011 ; Vol. 4.
@article{a1983a6b2d1441b8a77816b0f9fda1ef,
title = "Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy",
abstract = "Abstract. Background: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy. Methods. A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included. Results: Thirty-six patients (30.5{\%}) had a low absolute lymphocyte count (ALC, < 1.0 × 10 9 /L) at diagnosis. Patients with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/ high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was 25.0{\%} in the low ALC group and 4.8{\%} in the high ALC group (P = 0.003). In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P = 0.002, P = 0.001, respectively). Conclusion: This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.",
author = "Kim, {Yu Ri} and Jinseok Kim and Kim, {Soo Jeong} and Jung, {Hyun Ae} and Kim, {Seok Jin} and Kim, {Won Seog} and Lee, {Hye Won} and Eom, {Hyeon Seok} and Jeong, {Seong Hyun} and Park, {Joon Seong} and Cheong, {June Won} and Min, {Yoo Hong}",
year = "2011",
month = "8",
day = "17",
doi = "10.1186/1756-8722-4-34",
language = "English",
volume = "4",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",

}

Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. / Kim, Yu Ri; Kim, Jinseok; Kim, Soo Jeong; Jung, Hyun Ae; Kim, Seok Jin; Kim, Won Seog; Lee, Hye Won; Eom, Hyeon Seok; Jeong, Seong Hyun; Park, Joon Seong; Cheong, June Won; Min, Yoo Hong.

In: Journal of Hematology and Oncology, Vol. 4, 34, 17.08.2011.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

AU - Kim, Yu Ri

AU - Kim, Jinseok

AU - Kim, Soo Jeong

AU - Jung, Hyun Ae

AU - Kim, Seok Jin

AU - Kim, Won Seog

AU - Lee, Hye Won

AU - Eom, Hyeon Seok

AU - Jeong, Seong Hyun

AU - Park, Joon Seong

AU - Cheong, June Won

AU - Min, Yoo Hong

PY - 2011/8/17

Y1 - 2011/8/17

N2 - Abstract. Background: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy. Methods. A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included. Results: Thirty-six patients (30.5%) had a low absolute lymphocyte count (ALC, < 1.0 × 10 9 /L) at diagnosis. Patients with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/ high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was 25.0% in the low ALC group and 4.8% in the high ALC group (P = 0.003). In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P = 0.002, P = 0.001, respectively). Conclusion: This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.

AB - Abstract. Background: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy. Methods. A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included. Results: Thirty-six patients (30.5%) had a low absolute lymphocyte count (ALC, < 1.0 × 10 9 /L) at diagnosis. Patients with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/ high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was 25.0% in the low ALC group and 4.8% in the high ALC group (P = 0.003). In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P = 0.002, P = 0.001, respectively). Conclusion: This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.

UR - http://www.scopus.com/inward/record.url?scp=80051580303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051580303&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-4-34

DO - 10.1186/1756-8722-4-34

M3 - Article

VL - 4

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

M1 - 34

ER -